Search

News Ixekizumab administered for 5 years demonstrated high efficacy and a favorable safety profile in patients with moderate to severe psoriasis

Ixekizumab is a recombinant humanized monoclonal antibody against interleukin 17A, indicated for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. At the 24th World Congress of Dermatology in Milan in June 2019, results were presented from a study evaluating the efficacy and safety of long-term administration of ixekizumab.

Source: Biological Treatment 19. 5. 2020

News Pain Relief and Functional Score Improvement in Patients with Low Rheumatoid Arthritis Activity: Baricitinib vs. Adalimumab

In patients with rheumatoid arthritis, pain and functional impairment may persist even with good disease activity control. An exploratory analysis of the RA-BEAM study compared the effects of baricitinib, adalimumab, and placebo added to methotrexate on residual pain and functional scores in patients with rheumatoid arthritis (RA) who achieved remission or low disease activity with this treatment.

Source: Biological Treatment 20. 2. 2020

News Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype

A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic marker in chronic lymphocytic leukemia (CLL). An analysis of the impact of complex karyotype on the efficacy of targeted CLL therapy combining the monoclonal antibody against CD20 antigen obinutuzumab with the BCL2 inhibitor venetoclax or the alkylating cytostatic chlorambucil was published in the journal Blood.

Source: Chronic Lymphocytic Leukemia 22. 4. 2020

News Risk of Developing Inhibitors in People with Milder Forms of Hemophilia

Moderate and mild hemophilia A differ from the severe form not only in clinical course and bleeding risk, but also in the risk of developing neutralizing antibodies (inhibitors).

Source: Hemophilia 1. 11. 2021

News Fixed Combination of Tiotropium/Olodaterol in SMI Inhaler and Its Benefits in COPD Treatment

The TRONARTO study, whose conclusions were published in the International Journal of Chronic Obstructive Pulmonary Disease, addressed the issue of inhalation therapy in patients with chronic obstructive pulmonary disease (COPD). The authors focused on the effect of the combination of tiotropium and olodaterol in an SMI (soft mist inhaler) type inhaler.

Source: COPD 20. 12. 2021

News Good news for sleep in patients with axial spondyloarthritis –⁠ ixekizumab effectively reduces night-time back pain

The targeted treatment of axial spondyloarthritis currently relies on the anti-inflammatory effects of tumor necrosis factor (TNF) inhibitors, interleukin IL-17 inhibitors, and Janus kinase (JAK) inhibitors. Besides the objective efficacy of these targeted treatments, it is crucial to describe their influence on subjective symptoms for decision-making in clinical practice. The evaluation of the analgesic effect of ixekizumab (IXE) was provided by the randomized controlled trial COAST-V.

Source: Biological Treatment 14. 11. 2022

News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.

Source: Hemophilia with Movement 30. 5. 2022

News Third Generation Targeted Therapy for ROS1-Positive NSCLC

The potent third-generation tyrosine kinase inhibitor, lorlatinib, has shown activity in preclinical studies against nearly all known mutations in the ALK and ROS1 genes that lead to resistance to crizotinib treatment. Moreover, lorlatinib crosses the blood-brain barrier, offering hope for patients with CNS metastases. The results of a clinical evaluation of the efficacy and safety of lorlatinib in patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) were published in The Lancet Oncology.

Source: Genetic Profile and Treatment of NSCLC 15. 4. 2020

News Alemtuzumab –⁠ Does Age Matter? Or Not?

The authors of a study published this year focused on the safety and efficacy of alemtuzumab in patients with relapsing-remitting multiple sclerosis (RRMS). How did it perform over the observed period in patients of different age categories?

Source: Multiple Sclerosis 18. 10. 2021

News Subcutaneous pdC1-INH in Patients with Hereditary Angioedema in Real-World Practice

Italian authors published a series of cases of patients with hereditary angioedema caused by C1 inhibitor deficiency (C1-INH-HAE) with long-term prophylaxis using human plasma-derived C1 inhibitor concentrate (pdC1-INH) in subcutaneous form. They supplement the results of the placebo-controlled COMPACT study, in which s.c. pdC1-INH reduced the frequency of attacks, with insights from real-world practice in 5 patients treated at the angioedema therapy center in Milan, Italy.

Source: Hereditary Angioedema 27. 4. 2023

News Positive Effect of Diosmin on Venous Disease in Terms of Factors Responsible for Angiogenesis

A study published last year monitored the impact of diosmin on laboratory and clinical parameters related to the pathophysiology of chronic venous disease in patients.

Source: Venous Insufficiency 23. 4. 2020

News Clinical Characteristics of Trauma Patients Requiring Dosing Adjustments of Enoxaparin in TEN Prevention

Injuries and trauma surgical procedures represent a significant risk factor for the development of thromboembolic disease (TEN). Routine thromboprophylaxis is thus recommended for trauma patients, often in the form of low molecular weight heparins (LMWH), including enoxaparin. A recently published study evaluated factors associated with the need for higher dosing of enoxaparin to achieve effective prophylactic levels.

Source: Thromboprophylaxis 4. 11. 2021

News Is It Better to Switch or Cycle in the Treatment of Rheumatoid Arthritis?

The ideal strategy for treating rheumatoid arthritis is still the subject of research. We therefore present the results of a recent study comparing the impact of various therapeutic options when biological treatment is ineffective.

Source: Arthritis 24. 9. 2020

News Options for Modifying and Improving the Efficiency of the HJHS Scoring System

The Hemophilia Joint Health Score (HJHS) is a validated tool for assessing joint health in individuals with hemophilia. Can it be modified to be used more effectively in clinical practice?

Source: Hemophilia with Movement 30. 11. 2020

News Does the type of oral anticoagulant affect heparin dosing during catheter ablation?

During catheter ablation, which patients undergo as part of atrial fibrillation (AF) treatment, current guidelines recommend the administration of heparin without interrupting oral anticoagulant therapy. A recently published analysis evaluated whether the type of oral anticoagulant affects the total dose of heparin administered during the ablation.

Source: Anticoagulant Treatment 22. 3. 2021